Navigation Links
Monoclonal antibody reduces exacerbations in asthmatics

Patients with symptomatic moderate asthma who were treated with anti-tumor necrosis factor alpha, an anti-inflammatory monoclonal antibody, experienced significantly fewer disease exacerbations than individuals taking a placebo.

This research appears in the first issue for October 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

Trevor T. Hansel, M.D., Ph.D., of the National Heart and Lung Institute at Royal Brompton Hospital in London, and 11 associates infused 14 patients with infliximab, a monoclonal antibody that binds and neutralizes tumor necrosis factor alpha (TNFá). Eighteen patients received placebo during the eight-week double-blind study.

According to the investigators, both structured and inflammatory cells in asthmatics can release TNFá, which is an intercellular messenger protein, a cytokine, produced by white blood cells.

"Anti-TNFá therapy has been shown to be effective in patients with rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and psoriasis, but ineffective in patients with chronic obstructive pulmonary disease (COPD)," said Dr. Hansel. "Preliminary reports of efficacy in asthma patients with concomitant rheumatoid arthritis have been encouraging. Small prospective studies of a soluble receptor directed against TNFá in severe refractory asthma have also shown improvements in lung function and airway hyperresponsiveness."

During the study, 13 of the 18 patients on placebo (72 percent) experienced exacerbations, as compared to only four out of 14 patients (29 percent) on infliximab therapy.

All patients in the study cohort continued to use inhaled corticosteroids for their asthma. Study protocol required them to be symptomatic during a two- to four-week run-in period.

After the run-in phase, infusions of either infliximab or placebo were administered at weeks zero, two and six.

"Treatment with inflixima b reduced the number of moderate exacerbations in patients with asthma, as monitored by morning and evening use of an electronic spirometer incorporating a clinical diary," said Dr. Hansel. "Although infliximab therapy did not show significant efficacy for the primary endpoint of monitoring peak expiratory flow (PEF), it did produce a significant decrease in the diurnal (during the day) variation in the PEF rate."

(With PEF monitoring, patients take as deep as a breath as possible, then exhale as forcefully as possible into the mouthpiece of the PEF meter for three tests. As a gauge for pulmonary function, it is especially useful in patients older than age five who have persistent moderate to severe asthma.)

"None of the exacerbations we saw in our study warranted treatment with oral corticosteroids or hospitalization, so they cannot be considered to have been severe," said Dr. Hansel.

The researchers noted there were no adverse events associated with using the monoclonal antibody for treatment.

"Given that infliximab therapy was well-tolerated and appeared to reduce the incidence of asthma exacerbations, anti-TNFá therapy merits further study in larger clinical trials in patients with severe asthma," concluded Dr. Hansel.


'"/>

Source:American Thoracic Society


Related biology news :

1. Secrets to antibodys success against West Nile Virus surprise scientists
2. New antibody shows promise as cure for anthrax
3. Computer models aid understanding of antibody-dependent enhancement in spread of dengue fever
4. High resolution snapshots detail dynamics of a cocaine antibody
5. Buckyballs boost antibodys chemotherapy payload
6. Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
7. A single sugar found responsible for an antibodys ability to treat inflammation
8. A key antibody, IgG, links cells capture and disposal of germs
9. Male circumcision reduces risk of HIV transmission from women to men
10. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
11. New miniaturised chip dramatically reduces time taken for DNA analysis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):
(Date:8/11/2017)... (PRWEB) , ... August 11, 2017 , ... A staple ... campaign this month that will incorporate important key elements including a new digital marketing ... community that has supported them, Bill Miller has partnered with the South Texas Blood ...
(Date:8/11/2017)... (PRWEB) , ... August 11, 2017 , ... ... food production, and, in particular, more natural alternatives to synthetic ingredients,” said Matt ... of Third Wave, with the established manufacturing presence and know-how of Biorigin will ...
(Date:8/10/2017)... , ... August 09, 2017 , ... ... classroom next week-- as students. From August 14th through the 16th, the University ... which debuted in the summer of 2016, provides Philadelphia-based middle school educators an ...
(Date:8/10/2017)... NC (PRWEB) , ... August 09, 2017 , ... Each ... Almost half never recover well enough to live an independent lifestyle and, even worse, ... , A new discovery by doctors at the University of California Davis Medical Center ...
Breaking Biology Technology: